© 2002 European Society of Cardiology
The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy
Department of Cardiology, Baragwanath Hospital University of the Witwatersrand, PO Bertsham 2013, Johannesburg, South Africa
* Corresponding author. Tel.: +27-11-933-8197; fax: +27-11-938-8945. E-mail address: hahnle{at}netactive.co.za
 |
Abstract |
|---|
We have reported previously that despite treatment with angiotensin-converting enzyme inhibitors and β blockers, the outcome of patients with peripartum cardiomyopathy (PPC) remains unfavorable. Similar to other etiologies of left ventricular dysfunction, we found elevated levels of tumor necrosis factor-
(TNF-) in this group of patients. In the present study we sought to evaluate the effects of pentoxifylline, a drug known to inhibit the production of TNF-, on clinical status, left ventricular function, and circulating plasma levels of TNF-, in patients with PPC. We followed prospectively 59 consecutive women with PPC. The first 29 patients (group 1) were treated with diuretics, digoxin, enalapril and carvedilol. The next 30 consecutive patients (group 2) received pentoxifylline 400 mg TID in addition to the previous therapy. Clinical evaluation, echocardiograms and TNF- determinations were performed at baseline and after 6 months of treatment. Patients in the pentoxifylline group were older and had a higher E/A ratio. Nine patients died (eight in group 1, P=0.009 between groups). A combined end-point of poor outcome defined as either death, failure to improve the left ventricular ejection fraction >10 absolute points or functional class III or IV at latest follow-up, occurred in 52% of patients in group 1 and 27% of patients in group 2 (P=0.03). Treatment with pentoxifylline (P=0.04) was the only independent predictor of outcome. In conclusion, the results of this study suggest that the addition of pentoxifylline to conventional treatment, improves outcome in patients with peripartum cardiomyopathy.
Key Words: Cardiomyopathy • Cytokines • Heart failure
Received June 29, 2001; Revised August 3, 2001; Accepted October 23, 2001
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. Pandit, S. Shetty, A. Kumar, and A. Sagir Incidence and outcome of peripartum cardiomyopathy from a tertiary hospital in South India Trop Doct, July 1, 2009; 39(3): 168 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. RAMARAJ and V. L. SORRELL Peripartum cardiomyopathy: Causes, diagnosis, and treatment Cleveland Clinic Journal of Medicine, May 1, 2009; 76(5): 289 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S.S.G. de Jong, K. Rietveld, L. T. van Lochem, and B. J. Bouma Rapid left ventricular recovery after cabergoline treatment in a patient with peripartum cardiomyopathy Eur J Heart Fail, February 1, 2009; 11(2): 220 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Shaw, M. K.H. Shah, S. G. Williams, and J. E. Fildes Immunological mechanisms of pentoxifylline in chronic heart failure Eur J Heart Fail, February 1, 2009; 11(2): 113 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Forster, D. Hilfiker-Kleiner, A. A. Ansari, J. B. Sundstrom, E. Libhaber, W. Tshani, A. Becker, A. Yip, G. Klein, and K. Sliwa Reversal of IFN-{gamma}, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy Eur J Heart Fail, September 1, 2008; 10(9): 861 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Guggilam, M. Haque, E. K. Kerut, E. McIlwain, P. Lucchesi, I. Seghal, and J. Francis TNF-{alpha} blockade decreases oxidative stress in the paraventricular nucleus and attenuates sympathoexcitation in heart failure rats Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H599 - H609. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sliwa, O. Forster, E. Libhaber, J. D. Fett, J. B. Sundstrom, D. Hilfiker-Kleiner, and A. A. Ansari Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients Eur. Heart J., February 2, 2006; 27(4): 441 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sliwa, A. Damasceno, and B. M. Mayosi Epidemiology and Etiology of Cardiomyopathy in Africa Circulation, December 6, 2005; 112(23): 3577 - 3583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bahrmann, U. M. Hengst, B. M. Richartz, and H. R. Figulla Pentoxifylline in ischemic, hypertensive and idiopathic-dilated cardiomyopathy: effects on left-ventricular function, inflammatory cytokines and symptoms Eur J Heart Fail, March 1, 2004; 6(2): 195 - 201. [Abstract] [Full Text] [PDF]
|
|